nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—SLC22A5—Dactinomycin—skin cancer	0.144	0.205	CbGbCtD
Epinephrine—CYP1A2—Imiquimod—skin cancer	0.115	0.164	CbGbCtD
Epinephrine—CYP2C9—Vismodegib—skin cancer	0.0717	0.102	CbGbCtD
Epinephrine—CYP1A2—Vemurafenib—skin cancer	0.0629	0.0897	CbGbCtD
Epinephrine—CYP3A4—Imiquimod—skin cancer	0.0601	0.0857	CbGbCtD
Epinephrine—CYP3A4—Temozolomide—skin cancer	0.0601	0.0857	CbGbCtD
Epinephrine—CYP1A2—Dacarbazine—skin cancer	0.0482	0.0687	CbGbCtD
Epinephrine—CYP3A4—Vismodegib—skin cancer	0.0417	0.0594	CbGbCtD
Epinephrine—CYP3A4—Vemurafenib—skin cancer	0.0329	0.047	CbGbCtD
Epinephrine—CYP1A2—Fluorouracil—skin cancer	0.0283	0.0403	CbGbCtD
Epinephrine—CYP2C9—Fluorouracil—skin cancer	0.0255	0.0363	CbGbCtD
Epinephrine—CYP3A4—Docetaxel—skin cancer	0.0113	0.0161	CbGbCtD
Epinephrine—Ischaemia—Imiquimod—skin cancer	0.00679	0.0426	CcSEcCtD
Epinephrine—Local reaction—Imiquimod—skin cancer	0.00447	0.0281	CcSEcCtD
Epinephrine—Rales—Bleomycin—skin cancer	0.00429	0.0269	CcSEcCtD
Epinephrine—Hemiplegia—Temozolomide—skin cancer	0.00416	0.0261	CcSEcCtD
Epinephrine—Supraventricular tachycardia—Imiquimod—skin cancer	0.00378	0.0237	CcSEcCtD
Epinephrine—Local reaction—Bleomycin—skin cancer	0.00318	0.0199	CcSEcCtD
Epinephrine—Hypokalaemia—Vismodegib—skin cancer	0.00311	0.0195	CcSEcCtD
Epinephrine—Tingling sensation—Imiquimod—skin cancer	0.00308	0.0193	CcSEcCtD
Epinephrine—Cerebral haemorrhage—Temozolomide—skin cancer	0.00268	0.0168	CcSEcCtD
Epinephrine—Local reaction—Fluorouracil—skin cancer	0.00247	0.0155	CcSEcCtD
Epinephrine—Skin exfoliation—Imiquimod—skin cancer	0.00236	0.0148	CcSEcCtD
Epinephrine—Pulmonary oedema—Imiquimod—skin cancer	0.0022	0.0138	CcSEcCtD
Epinephrine—Necrosis—Dactinomycin—skin cancer	0.00209	0.0131	CcSEcCtD
Epinephrine—Extravasation—Bleomycin—skin cancer	0.00202	0.0126	CcSEcCtD
Epinephrine—Memory impairment—Temozolomide—skin cancer	0.00189	0.0119	CcSEcCtD
Epinephrine—Extravasation—Dactinomycin—skin cancer	0.00188	0.0118	CcSEcCtD
Epinephrine—Cerebrovascular accident—Imiquimod—skin cancer	0.00183	0.0115	CcSEcCtD
Epinephrine—Necrosis—Fluorouracil—skin cancer	0.00174	0.0109	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00174	0.0109	CcSEcCtD
Epinephrine—Tingling sensation—Fluorouracil—skin cancer	0.0017	0.0107	CcSEcCtD
Epinephrine—Myocardial ischaemia—Fluorouracil—skin cancer	0.0017	0.0107	CcSEcCtD
Epinephrine—Skin exfoliation—Bleomycin—skin cancer	0.00168	0.0105	CcSEcCtD
Epinephrine—Nervous system disorder—Vismodegib—skin cancer	0.00164	0.0103	CcSEcCtD
Epinephrine—Skin disorder—Vismodegib—skin cancer	0.00163	0.0102	CcSEcCtD
Epinephrine—Extravasation—Fluorouracil—skin cancer	0.00157	0.00983	CcSEcCtD
Epinephrine—Sweating increased—Imiquimod—skin cancer	0.00151	0.00949	CcSEcCtD
Epinephrine—Supraventricular tachycardia—Docetaxel—skin cancer	0.00151	0.00945	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00145	0.00908	CcSEcCtD
Epinephrine—Disorientation—Bleomycin—skin cancer	0.00143	0.00896	CcSEcCtD
Epinephrine—Skin exfoliation—Temozolomide—skin cancer	0.00142	0.00889	CcSEcCtD
Epinephrine—Acute coronary syndrome—Imiquimod—skin cancer	0.00137	0.00857	CcSEcCtD
Epinephrine—Myocardial infarction—Imiquimod—skin cancer	0.00136	0.00852	CcSEcCtD
Epinephrine—Cerebrovascular accident—Bleomycin—skin cancer	0.0013	0.00817	CcSEcCtD
Epinephrine—Erythema—Vemurafenib—skin cancer	0.00127	0.00796	CcSEcCtD
Epinephrine—Necrosis—Docetaxel—skin cancer	0.00126	0.00789	CcSEcCtD
Epinephrine—Haemoglobin—Imiquimod—skin cancer	0.00125	0.00784	CcSEcCtD
Epinephrine—Haemorrhage—Imiquimod—skin cancer	0.00124	0.0078	CcSEcCtD
Epinephrine—Myocardial ischaemia—Docetaxel—skin cancer	0.00123	0.0077	CcSEcCtD
Epinephrine—Flushing—Imiquimod—skin cancer	0.00115	0.00724	CcSEcCtD
Epinephrine—Extravasation—Docetaxel—skin cancer	0.00113	0.0071	CcSEcCtD
Epinephrine—Arrhythmia—Imiquimod—skin cancer	0.00111	0.00697	CcSEcCtD
Epinephrine—Disorientation—Fluorouracil—skin cancer	0.00111	0.00696	CcSEcCtD
Epinephrine—Mental disorder—Imiquimod—skin cancer	0.00109	0.00683	CcSEcCtD
Epinephrine—Erythema—Imiquimod—skin cancer	0.00108	0.00679	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00107	0.00673	CcSEcCtD
Epinephrine—Vomiting—Vismodegib—skin cancer	0.00107	0.00669	CcSEcCtD
Epinephrine—Drug interaction—Docetaxel—skin cancer	0.00106	0.00667	CcSEcCtD
Epinephrine—Nervous system disorder—Vemurafenib—skin cancer	0.00102	0.00637	CcSEcCtD
Epinephrine—Skin disorder—Vemurafenib—skin cancer	0.00101	0.00631	CcSEcCtD
Epinephrine—Nausea—Vismodegib—skin cancer	0.000996	0.00625	CcSEcCtD
Epinephrine—Agitation—Imiquimod—skin cancer	0.000995	0.00624	CcSEcCtD
Epinephrine—Blood pressure increased—Docetaxel—skin cancer	0.000987	0.00619	CcSEcCtD
Epinephrine—Hypokalaemia—Temozolomide—skin cancer	0.00098	0.00615	CcSEcCtD
Epinephrine—Acute coronary syndrome—Bleomycin—skin cancer	0.00097	0.00609	CcSEcCtD
Epinephrine—Myocardial infarction—Bleomycin—skin cancer	0.000965	0.00605	CcSEcCtD
Epinephrine—Palpitations—Imiquimod—skin cancer	0.000957	0.006	CcSEcCtD
Epinephrine—Skin exfoliation—Docetaxel—skin cancer	0.000942	0.00591	CcSEcCtD
Epinephrine—ADRB3—connective tissue—skin cancer	0.00094	0.077	CbGeAlD
Epinephrine—Hypertension—Imiquimod—skin cancer	0.000935	0.00586	CcSEcCtD
Epinephrine—Chest pain—Imiquimod—skin cancer	0.000922	0.00578	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000915	0.00574	CcSEcCtD
Epinephrine—Sweating increased—Temozolomide—skin cancer	0.000907	0.00569	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000894	0.00561	CcSEcCtD
Epinephrine—Haemoglobin—Bleomycin—skin cancer	0.000888	0.00557	CcSEcCtD
Epinephrine—Haemorrhage—Bleomycin—skin cancer	0.000884	0.00554	CcSEcCtD
Epinephrine—Lightheadedness—Docetaxel—skin cancer	0.000883	0.00554	CcSEcCtD
Epinephrine—Hypoaesthesia—Bleomycin—skin cancer	0.000879	0.00551	CcSEcCtD
Epinephrine—Pulmonary oedema—Docetaxel—skin cancer	0.000879	0.00551	CcSEcCtD
Epinephrine—Nervous system disorder—Imiquimod—skin cancer	0.000867	0.00544	CcSEcCtD
Epinephrine—Tachycardia—Imiquimod—skin cancer	0.000862	0.00541	CcSEcCtD
Epinephrine—Skin disorder—Imiquimod—skin cancer	0.000858	0.00538	CcSEcCtD
Epinephrine—Hyperhidrosis—Imiquimod—skin cancer	0.000854	0.00536	CcSEcCtD
Epinephrine—Hyperglycaemia—Temozolomide—skin cancer	0.00084	0.00527	CcSEcCtD
Epinephrine—Flushing—Bleomycin—skin cancer	0.00082	0.00514	CcSEcCtD
Epinephrine—Insomnia—Imiquimod—skin cancer	0.000799	0.00501	CcSEcCtD
Epinephrine—Paraesthesia—Imiquimod—skin cancer	0.000793	0.00498	CcSEcCtD
Epinephrine—Somnolence—Imiquimod—skin cancer	0.000786	0.00493	CcSEcCtD
Epinephrine—Erythema—Bleomycin—skin cancer	0.000769	0.00482	CcSEcCtD
Epinephrine—Flushing—Dactinomycin—skin cancer	0.000765	0.0048	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000763	0.00478	CcSEcCtD
Epinephrine—Acute coronary syndrome—Fluorouracil—skin cancer	0.000754	0.00473	CcSEcCtD
Epinephrine—Renal impairment—Docetaxel—skin cancer	0.000753	0.00472	CcSEcCtD
Epinephrine—Myocardial infarction—Fluorouracil—skin cancer	0.00075	0.0047	CcSEcCtD
Epinephrine—Haemoglobin—Temozolomide—skin cancer	0.000749	0.0047	CcSEcCtD
Epinephrine—Haemorrhage—Temozolomide—skin cancer	0.000745	0.00467	CcSEcCtD
Epinephrine—Hallucination—Temozolomide—skin cancer	0.000742	0.00465	CcSEcCtD
Epinephrine—Hypoaesthesia—Temozolomide—skin cancer	0.000742	0.00465	CcSEcCtD
Epinephrine—Erythema—Dactinomycin—skin cancer	0.000717	0.0045	CcSEcCtD
Epinephrine—PAH—head—skin cancer	0.000709	0.0581	CbGeAlD
Epinephrine—Flushing—Temozolomide—skin cancer	0.000692	0.00434	CcSEcCtD
Epinephrine—Haemoglobin—Fluorouracil—skin cancer	0.00069	0.00433	CcSEcCtD
Epinephrine—Haemorrhage—Fluorouracil—skin cancer	0.000687	0.00431	CcSEcCtD
Epinephrine—Dizziness—Vemurafenib—skin cancer	0.000685	0.0043	CcSEcCtD
Epinephrine—Hypoaesthesia—Fluorouracil—skin cancer	0.000683	0.00429	CcSEcCtD
Epinephrine—ADRBK1—lymphoid tissue—skin cancer	0.000672	0.055	CbGeAlD
Epinephrine—ADRB3—female reproductive system—skin cancer	0.000663	0.0543	CbGeAlD
Epinephrine—TNF—lymph node—skin cancer	0.00066	0.0541	CbGeAlD
Epinephrine—Vomiting—Vemurafenib—skin cancer	0.000659	0.00413	CcSEcCtD
Epinephrine—Chest pain—Bleomycin—skin cancer	0.000655	0.00411	CcSEcCtD
Epinephrine—Mental disorder—Temozolomide—skin cancer	0.000653	0.0041	CcSEcCtD
Epinephrine—Erythema—Temozolomide—skin cancer	0.000649	0.00407	CcSEcCtD
Epinephrine—ADRBK1—female reproductive system—skin cancer	0.000648	0.0531	CbGeAlD
Epinephrine—Nausea—Vemurafenib—skin cancer	0.000615	0.00386	CcSEcCtD
Epinephrine—Arrhythmia—Fluorouracil—skin cancer	0.000613	0.00385	CcSEcCtD
Epinephrine—Erythema—Fluorouracil—skin cancer	0.000598	0.00375	CcSEcCtD
Epinephrine—Agitation—Temozolomide—skin cancer	0.000596	0.00374	CcSEcCtD
Epinephrine—Dizziness—Imiquimod—skin cancer	0.000584	0.00366	CcSEcCtD
Epinephrine—Palpitations—Temozolomide—skin cancer	0.000573	0.0036	CcSEcCtD
Epinephrine—Paraesthesia—Bleomycin—skin cancer	0.000564	0.00354	CcSEcCtD
Epinephrine—Vomiting—Imiquimod—skin cancer	0.000562	0.00352	CcSEcCtD
Epinephrine—Hypertension—Temozolomide—skin cancer	0.00056	0.00351	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000549	0.00344	CcSEcCtD
Epinephrine—Acute coronary syndrome—Docetaxel—skin cancer	0.000544	0.00341	CcSEcCtD
Epinephrine—Renal failure—Docetaxel—skin cancer	0.000543	0.0034	CcSEcCtD
Epinephrine—ADRBK1—head—skin cancer	0.000541	0.0443	CbGeAlD
Epinephrine—Myocardial infarction—Docetaxel—skin cancer	0.000541	0.00339	CcSEcCtD
Epinephrine—Nausea—Imiquimod—skin cancer	0.000525	0.00329	CcSEcCtD
Epinephrine—Nervous system disorder—Temozolomide—skin cancer	0.000519	0.00326	CcSEcCtD
Epinephrine—Skin disorder—Temozolomide—skin cancer	0.000514	0.00323	CcSEcCtD
Epinephrine—Hyperhidrosis—Temozolomide—skin cancer	0.000512	0.00321	CcSEcCtD
Epinephrine—Chest pain—Fluorouracil—skin cancer	0.000509	0.00319	CcSEcCtD
Epinephrine—ADRA1D—epithelium—skin cancer	0.000502	0.0411	CbGeAlD
Epinephrine—Haemoglobin—Docetaxel—skin cancer	0.000498	0.00312	CcSEcCtD
Epinephrine—Haemorrhage—Docetaxel—skin cancer	0.000496	0.00311	CcSEcCtD
Epinephrine—Hypoaesthesia—Docetaxel—skin cancer	0.000493	0.00309	CcSEcCtD
Epinephrine—Insomnia—Temozolomide—skin cancer	0.000479	0.003	CcSEcCtD
Epinephrine—Nervous system disorder—Fluorouracil—skin cancer	0.000478	0.003	CcSEcCtD
Epinephrine—Tachycardia—Fluorouracil—skin cancer	0.000476	0.00299	CcSEcCtD
Epinephrine—Paraesthesia—Temozolomide—skin cancer	0.000475	0.00298	CcSEcCtD
Epinephrine—Somnolence—Temozolomide—skin cancer	0.000471	0.00295	CcSEcCtD
Epinephrine—Flushing—Docetaxel—skin cancer	0.00046	0.00289	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000457	0.00287	CcSEcCtD
Epinephrine—Arrhythmia—Docetaxel—skin cancer	0.000443	0.00278	CcSEcCtD
Epinephrine—Insomnia—Fluorouracil—skin cancer	0.000441	0.00277	CcSEcCtD
Epinephrine—Paraesthesia—Fluorouracil—skin cancer	0.000438	0.00275	CcSEcCtD
Epinephrine—Mental disorder—Docetaxel—skin cancer	0.000434	0.00272	CcSEcCtD
Epinephrine—Somnolence—Fluorouracil—skin cancer	0.000434	0.00272	CcSEcCtD
Epinephrine—Erythema—Docetaxel—skin cancer	0.000431	0.00271	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000421	0.00264	CcSEcCtD
Epinephrine—ADRA2C—nipple—skin cancer	0.000408	0.0334	CbGeAlD
Epinephrine—Vomiting—Bleomycin—skin cancer	0.000399	0.0025	CcSEcCtD
Epinephrine—SLC22A5—nipple—skin cancer	0.000391	0.032	CbGeAlD
Epinephrine—ADRB1—connective tissue—skin cancer	0.000384	0.0315	CbGeAlD
Epinephrine—Palpitations—Docetaxel—skin cancer	0.000381	0.00239	CcSEcCtD
Epinephrine—ADRBK1—lymph node—skin cancer	0.000379	0.031	CbGeAlD
Epinephrine—ADRA1D—female reproductive system—skin cancer	0.000373	0.0306	CbGeAlD
Epinephrine—Nausea—Bleomycin—skin cancer	0.000373	0.00234	CcSEcCtD
Epinephrine—Hypertension—Docetaxel—skin cancer	0.000373	0.00234	CcSEcCtD
Epinephrine—Vomiting—Dactinomycin—skin cancer	0.000372	0.00233	CcSEcCtD
Epinephrine—Chest pain—Docetaxel—skin cancer	0.000367	0.0023	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000365	0.00229	CcSEcCtD
Epinephrine—CYP1A2—nipple—skin cancer	0.000354	0.029	CbGeAlD
Epinephrine—Dizziness—Temozolomide—skin cancer	0.00035	0.0022	CcSEcCtD
Epinephrine—Nausea—Dactinomycin—skin cancer	0.000348	0.00218	CcSEcCtD
Epinephrine—Nervous system disorder—Docetaxel—skin cancer	0.000345	0.00217	CcSEcCtD
Epinephrine—Tachycardia—Docetaxel—skin cancer	0.000344	0.00216	CcSEcCtD
Epinephrine—Skin disorder—Docetaxel—skin cancer	0.000342	0.00215	CcSEcCtD
Epinephrine—Vomiting—Temozolomide—skin cancer	0.000337	0.00211	CcSEcCtD
Epinephrine—ADRA2A—nipple—skin cancer	0.000326	0.0267	CbGeAlD
Epinephrine—Dizziness—Fluorouracil—skin cancer	0.000323	0.00202	CcSEcCtD
Epinephrine—ADRA1B—head—skin cancer	0.000319	0.0261	CbGeAlD
Epinephrine—Insomnia—Docetaxel—skin cancer	0.000318	0.002	CcSEcCtD
Epinephrine—Paraesthesia—Docetaxel—skin cancer	0.000316	0.00198	CcSEcCtD
Epinephrine—Nausea—Temozolomide—skin cancer	0.000315	0.00197	CcSEcCtD
Epinephrine—Somnolence—Docetaxel—skin cancer	0.000313	0.00196	CcSEcCtD
Epinephrine—ADRA1D—head—skin cancer	0.000312	0.0255	CbGeAlD
Epinephrine—Vomiting—Fluorouracil—skin cancer	0.00031	0.00195	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000304	0.00191	CcSEcCtD
Epinephrine—Nausea—Fluorouracil—skin cancer	0.00029	0.00182	CcSEcCtD
Epinephrine—ADRA1A—epithelium—skin cancer	0.000289	0.0236	CbGeAlD
Epinephrine—ADRB1—female reproductive system—skin cancer	0.000271	0.0222	CbGeAlD
Epinephrine—SLC22A5—skin of body—skin cancer	0.000251	0.0205	CbGeAlD
Epinephrine—ADRA2C—mammalian vulva—skin cancer	0.000239	0.0195	CbGeAlD
Epinephrine—SLC22A1—head—skin cancer	0.000235	0.0193	CbGeAlD
Epinephrine—Dizziness—Docetaxel—skin cancer	0.000233	0.00146	CcSEcCtD
Epinephrine—ADRA2A—connective tissue—skin cancer	0.000231	0.0189	CbGeAlD
Epinephrine—ADRB1—head—skin cancer	0.000227	0.0185	CbGeAlD
Epinephrine—Vomiting—Docetaxel—skin cancer	0.000224	0.0014	CcSEcCtD
Epinephrine—ADRA1A—lymphoid tissue—skin cancer	0.000222	0.0182	CbGeAlD
Epinephrine—Nausea—Docetaxel—skin cancer	0.000209	0.00131	CcSEcCtD
Epinephrine—SLC22A5—female reproductive system—skin cancer	0.000196	0.016	CbGeAlD
Epinephrine—ADRA2A—mammalian vulva—skin cancer	0.00019	0.0156	CbGeAlD
Epinephrine—ADRA1A—head—skin cancer	0.000179	0.0147	CbGeAlD
Epinephrine—ADRA2C—head—skin cancer	0.000171	0.014	CbGeAlD
Epinephrine—CYP2C9—female reproductive system—skin cancer	0.000168	0.0138	CbGeAlD
Epinephrine—ADRA2A—female reproductive system—skin cancer	0.000163	0.0133	CbGeAlD
Epinephrine—ADRA2A—head—skin cancer	0.000136	0.0112	CbGeAlD
Epinephrine—CYP3A4—female reproductive system—skin cancer	0.000128	0.0105	CbGeAlD
Epinephrine—ADRA2C—lymph node—skin cancer	0.00012	0.00979	CbGeAlD
Epinephrine—SLC22A5—lymph node—skin cancer	0.000114	0.00937	CbGeAlD
Epinephrine—ADRA2A—lymph node—skin cancer	9.54e-05	0.00781	CbGeAlD
Epinephrine—ADRB2—Signaling Pathways—SUFU—skin cancer	4.91e-05	0.000387	CbGpPWpGaD
Epinephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	4.91e-05	0.000387	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—GLI1—skin cancer	4.9e-05	0.000386	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MC1R—skin cancer	4.89e-05	0.000385	CbGpPWpGaD
Epinephrine—PAH—Disease—NRAS—skin cancer	4.87e-05	0.000384	CbGpPWpGaD
Epinephrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.87e-05	0.000384	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—SHH—skin cancer	4.87e-05	0.000383	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—PTGER4—skin cancer	4.83e-05	0.000381	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—GLI1—skin cancer	4.82e-05	0.00038	CbGpPWpGaD
Epinephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	4.75e-05	0.000375	CbGpPWpGaD
Epinephrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.66e-05	0.000367	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SUFU—skin cancer	4.64e-05	0.000366	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—SMO—skin cancer	4.61e-05	0.000364	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PTCH1—skin cancer	4.61e-05	0.000364	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SUFU—skin cancer	4.57e-05	0.00036	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—GLI2—skin cancer	4.55e-05	0.000359	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PTGER4—skin cancer	4.49e-05	0.000354	CbGpPWpGaD
Epinephrine—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	4.47e-05	0.000352	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—TERT—skin cancer	4.37e-05	0.000344	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—ENO2—skin cancer	4.35e-05	0.000343	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MC1R—skin cancer	4.34e-05	0.000342	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—GLI1—skin cancer	4.28e-05	0.000337	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—ENO2—skin cancer	4.23e-05	0.000334	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—GLI2—skin cancer	4.23e-05	0.000333	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—HRAS—skin cancer	4.23e-05	0.000333	CbGpPWpGaD
Epinephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	4.22e-05	0.000333	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SHH—skin cancer	4.2e-05	0.000331	CbGpPWpGaD
Epinephrine—PAH—Disease—KRAS—skin cancer	4.2e-05	0.000331	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—RASA1—skin cancer	4.17e-05	0.000329	CbGpPWpGaD
Epinephrine—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	4.17e-05	0.000328	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SUFU—skin cancer	4.06e-05	0.00032	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—ENO2—skin cancer	4.06e-05	0.00032	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PLIN2—skin cancer	4.05e-05	0.000319	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—IL6—skin cancer	4.04e-05	0.000319	CbGpPWpGaD
Epinephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.04e-05	0.000318	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MC1R—skin cancer	4.04e-05	0.000318	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—PTGS2—skin cancer	3.99e-05	0.000315	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PTCH1—skin cancer	3.98e-05	0.000314	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SMO—skin cancer	3.98e-05	0.000314	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—GLI1—skin cancer	3.98e-05	0.000313	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PTGER4—skin cancer	3.87e-05	0.000305	CbGpPWpGaD
Epinephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	3.87e-05	0.000305	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SHH—skin cancer	3.82e-05	0.000301	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—RASA1—skin cancer	3.8e-05	0.000299	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SHH—skin cancer	3.79e-05	0.000299	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SUFU—skin cancer	3.77e-05	0.000297	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—RASA1—skin cancer	3.77e-05	0.000297	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SHH—skin cancer	3.74e-05	0.000295	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—RASA1—skin cancer	3.72e-05	0.000293	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—NRAS—skin cancer	3.7e-05	0.000291	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—NRAS—skin cancer	3.68e-05	0.00029	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTCH1—skin cancer	3.63e-05	0.000286	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SMO—skin cancer	3.63e-05	0.000286	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTCH1—skin cancer	3.59e-05	0.000283	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SMO—skin cancer	3.59e-05	0.000283	CbGpPWpGaD
Epinephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	3.59e-05	0.000283	CbGpPWpGaD
Epinephrine—PAH—Disease—HRAS—skin cancer	3.57e-05	0.000281	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SMO—skin cancer	3.55e-05	0.000279	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTCH1—skin cancer	3.55e-05	0.000279	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SHH—skin cancer	3.54e-05	0.000279	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTGER4—skin cancer	3.53e-05	0.000278	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—RASA1—skin cancer	3.52e-05	0.000277	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—TERT—skin cancer	3.51e-05	0.000276	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTGER4—skin cancer	3.5e-05	0.000276	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SHH—skin cancer	3.48e-05	0.000274	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PLIN2—skin cancer	3.46e-05	0.000273	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—RASA1—skin cancer	3.46e-05	0.000273	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—BRAF—skin cancer	3.46e-05	0.000273	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTGER4—skin cancer	3.45e-05	0.000272	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—ENO2—skin cancer	3.44e-05	0.000271	CbGpPWpGaD
Epinephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	3.44e-05	0.000271	CbGpPWpGaD
Epinephrine—SLC22A2—Neuronal System—HRAS—skin cancer	3.43e-05	0.00027	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—FOXO4—skin cancer	3.42e-05	0.00027	CbGpPWpGaD
Epinephrine—PAH—Disease—IL6—skin cancer	3.41e-05	0.000269	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—NRAS—skin cancer	3.36e-05	0.000265	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SMO—skin cancer	3.36e-05	0.000264	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTCH1—skin cancer	3.36e-05	0.000264	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SMO—skin cancer	3.3e-05	0.00026	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTCH1—skin cancer	3.3e-05	0.00026	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CSPG4—skin cancer	3.27e-05	0.000257	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTGER4—skin cancer	3.27e-05	0.000257	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTGER4—skin cancer	3.22e-05	0.000253	CbGpPWpGaD
Epinephrine—SLC22A1—Neuronal System—HRAS—skin cancer	3.19e-05	0.000252	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—KRAS—skin cancer	3.18e-05	0.000251	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—KRAS—skin cancer	3.17e-05	0.00025	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—FOXO4—skin cancer	3.12e-05	0.000246	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—NRAS—skin cancer	3.11e-05	0.000245	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SHH—skin cancer	3.09e-05	0.000244	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—FOXO4—skin cancer	3.09e-05	0.000243	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—RASA1—skin cancer	3.08e-05	0.000242	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—FOXO4—skin cancer	3.05e-05	0.00024	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—NRAS—skin cancer	3.03e-05	0.000239	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—NRAS—skin cancer	2.96e-05	0.000233	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTCH1—skin cancer	2.93e-05	0.000231	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SMO—skin cancer	2.93e-05	0.000231	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—KRAS—skin cancer	2.9e-05	0.000228	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—FOXO4—skin cancer	2.89e-05	0.000227	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SHH—skin cancer	2.88e-05	0.000227	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—RASA1—skin cancer	2.86e-05	0.000225	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	2.86e-05	0.000225	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—FOXO4—skin cancer	2.84e-05	0.000224	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—NRAS—skin cancer	2.83e-05	0.000223	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CSPG4—skin cancer	2.79e-05	0.00022	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—BRAF—skin cancer	2.78e-05	0.000219	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SMO—skin cancer	2.73e-05	0.000215	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTCH1—skin cancer	2.73e-05	0.000215	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—HRAS—skin cancer	2.7e-05	0.000213	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—HRAS—skin cancer	2.69e-05	0.000212	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PLIN2—skin cancer	2.67e-05	0.000211	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—KRAS—skin cancer	2.67e-05	0.000211	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	2.65e-05	0.000209	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—KRAS—skin cancer	2.61e-05	0.000205	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—IL6—skin cancer	2.59e-05	0.000204	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—IL6—skin cancer	2.58e-05	0.000203	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—KRAS—skin cancer	2.54e-05	0.0002	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—ERCC2—skin cancer	2.53e-05	0.000199	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	2.52e-05	0.000199	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HRAS—skin cancer	2.46e-05	0.000194	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—ERCC2—skin cancer	2.46e-05	0.000194	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—KRAS—skin cancer	2.44e-05	0.000192	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—ERCC2—skin cancer	2.36e-05	0.000186	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IL6—skin cancer	2.36e-05	0.000186	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	2.34e-05	0.000185	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—TP53—skin cancer	2.32e-05	0.000183	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—NRAS—skin cancer	2.3e-05	0.000181	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TERT—skin cancer	2.29e-05	0.00018	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—HRAS—skin cancer	2.27e-05	0.000179	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—ENO2—skin cancer	2.22e-05	0.000175	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—HRAS—skin cancer	2.22e-05	0.000175	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—NRAS—skin cancer	2.18e-05	0.000171	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—IL6—skin cancer	2.17e-05	0.000171	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—TP53—skin cancer	2.16e-05	0.000171	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—HRAS—skin cancer	2.16e-05	0.00017	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CSPG4—skin cancer	2.16e-05	0.00017	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TERT—skin cancer	2.08e-05	0.000164	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—HRAS—skin cancer	2.07e-05	0.000163	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—IL6—skin cancer	2.07e-05	0.000163	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TERT—skin cancer	2.06e-05	0.000163	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TERT—skin cancer	2.04e-05	0.00016	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—ERCC2—skin cancer	2e-05	0.000157	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—KRAS—skin cancer	1.98e-05	0.000156	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TERT—skin cancer	1.93e-05	0.000152	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—NRAS—skin cancer	1.93e-05	0.000152	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ENO2—skin cancer	1.9e-05	0.00015	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TERT—skin cancer	1.9e-05	0.000149	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—KRAS—skin cancer	1.87e-05	0.000147	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—BRAF—skin cancer	1.81e-05	0.000143	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—TP53—skin cancer	1.76e-05	0.000139	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—NRAS—skin cancer	1.75e-05	0.000138	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—NRAS—skin cancer	1.75e-05	0.000138	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.74e-05	0.000137	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.74e-05	0.000137	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—NRAS—skin cancer	1.72e-05	0.000135	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TERT—skin cancer	1.69e-05	0.000133	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—HRAS—skin cancer	1.68e-05	0.000132	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—TP53—skin cancer	1.66e-05	0.000131	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—KRAS—skin cancer	1.66e-05	0.000131	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—BRAF—skin cancer	1.65e-05	0.00013	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.63e-05	0.000129	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.62e-05	0.000128	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—BRAF—skin cancer	1.61e-05	0.000127	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	1.6e-05	0.000126	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—HRAS—skin cancer	1.59e-05	0.000125	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TERT—skin cancer	1.57e-05	0.000123	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.53e-05	0.00012	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—IL6—skin cancer	1.52e-05	0.00012	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PTGS2—skin cancer	1.52e-05	0.000119	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—KRAS—skin cancer	1.51e-05	0.000119	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—KRAS—skin cancer	1.5e-05	0.000118	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—BRAF—skin cancer	1.5e-05	0.000118	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.5e-05	0.000118	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.48e-05	0.000117	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—KRAS—skin cancer	1.48e-05	0.000116	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PTGS2—skin cancer	1.47e-05	0.000116	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ENO2—skin cancer	1.47e-05	0.000115	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	1.42e-05	0.000112	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PTGS2—skin cancer	1.41e-05	0.000111	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—HRAS—skin cancer	1.41e-05	0.000111	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.4e-05	0.00011	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	1.38e-05	0.000108	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—IL6—skin cancer	1.35e-05	0.000106	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—TP53—skin cancer	1.34e-05	0.000105	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—BRAF—skin cancer	1.33e-05	0.000105	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.32e-05	0.000104	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—ERCC2—skin cancer	1.29e-05	0.000102	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—HRAS—skin cancer	1.28e-05	0.000101	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—HRAS—skin cancer	1.28e-05	0.000101	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—HRAS—skin cancer	1.27e-05	0.0001	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—HRAS—skin cancer	1.26e-05	9.89e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—BRAF—skin cancer	1.24e-05	9.77e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—IL6—skin cancer	1.23e-05	9.68e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—IL6—skin cancer	1.22e-05	9.63e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	1.22e-05	9.63e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—IL6—skin cancer	1.22e-05	9.59e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—IL6—skin cancer	1.2e-05	9.47e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTGS2—skin cancer	1.2e-05	9.44e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—HRAS—skin cancer	1.19e-05	9.36e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	1.17e-05	9.21e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—NRAS—skin cancer	1.14e-05	8.96e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—IL6—skin cancer	1.14e-05	8.96e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	1.14e-05	8.94e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—IL6—skin cancer	1.12e-05	8.82e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ERCC2—skin cancer	1.1e-05	8.69e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	1.04e-05	8.18e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—NRAS—skin cancer	1.04e-05	8.17e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—NRAS—skin cancer	1.03e-05	8.09e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—NRAS—skin cancer	1.01e-05	7.99e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—IL6—skin cancer	9.94e-06	7.83e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KRAS—skin cancer	9.79e-06	7.71e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	9.65e-06	7.6e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—NRAS—skin cancer	9.59e-06	7.56e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—NRAS—skin cancer	9.44e-06	7.44e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL6—skin cancer	9.24e-06	7.28e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KRAS—skin cancer	8.92e-06	7.03e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KRAS—skin cancer	8.84e-06	6.96e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KRAS—skin cancer	8.73e-06	6.88e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—skin cancer	8.7e-06	6.86e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ERCC2—skin cancer	8.51e-06	6.7e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NRAS—skin cancer	8.39e-06	6.61e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—HRAS—skin cancer	8.32e-06	6.56e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KRAS—skin cancer	8.26e-06	6.51e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KRAS—skin cancer	8.13e-06	6.4e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL6—skin cancer	7.97e-06	6.28e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—skin cancer	7.93e-06	6.25e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—skin cancer	7.86e-06	6.19e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NRAS—skin cancer	7.79e-06	6.14e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—skin cancer	7.76e-06	6.11e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTGS2—skin cancer	7.74e-06	6.1e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—HRAS—skin cancer	7.58e-06	5.97e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—HRAS—skin cancer	7.51e-06	5.92e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—HRAS—skin cancer	7.42e-06	5.84e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—skin cancer	7.34e-06	5.78e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL6—skin cancer	7.26e-06	5.72e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—skin cancer	7.22e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KRAS—skin cancer	7.22e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL6—skin cancer	7.19e-06	5.67e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL6—skin cancer	7.1e-06	5.59e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—HRAS—skin cancer	7.02e-06	5.53e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—HRAS—skin cancer	6.91e-06	5.44e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL6—skin cancer	6.72e-06	5.29e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KRAS—skin cancer	6.71e-06	5.28e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTGS2—skin cancer	6.61e-06	5.21e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL6—skin cancer	6.61e-06	5.21e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—skin cancer	6.42e-06	5.05e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—HRAS—skin cancer	6.14e-06	4.83e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—skin cancer	5.96e-06	4.7e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL6—skin cancer	5.87e-06	4.63e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—HRAS—skin cancer	5.7e-06	4.49e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL6—skin cancer	5.46e-06	4.3e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTGS2—skin cancer	5.1e-06	4.02e-05	CbGpPWpGaD
